Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
复制标题
急性淋巴细胞白血病儿童的十年生存率：儿童肿瘤学组的报告。
DOI：
10.1080/10428190802074593
复制
发表时间：
2008
影响因子：
2.6
通讯作者：
Children'sOncologyGroup
中科院分区：
文献类型：
--
作者：
Trigg,MichaelE;Sather,HarlandN;Reaman,GregoryH;Tubergen,DavidG;Steinherz,PeterG;Gaynon,PaulS;Uckun,FatihM;Hammond,GDenman;Children'sOncologyGroup
30年前，儿童癌症组织开始对儿童急性淋巴细胞白血病进行基于风险的分配。长期生存数据（至少随访>10年）现已可用。大约3711名符合条件的儿童参加了风险调整的治疗方案（1983-1989）。10年无事件生存率（EFS）和总生存率分别为62%（标准差[SD] = 1%）和73%（SD = 1%）。这些数据显示与先前研究相比有显著改善（P< 0.0001）。由于11%的初次复发患者存活，没有第二次事件，这些数据预测治愈率为73%。中危组（P< 0.0001）、高危组（P <0.0001）和淋巴瘤组（P<0.0001）患者的10年EFS和生存率显著提高。治疗的关键组成部分包括延迟强化和鞘内化疗替代低风险和中风险患者的预防性/预防性颅骨放疗。这是同时研究中观察超过10年的最大儿童系列。
The Children's Cancer Group initiated risk-based allocation for childhood acute lymphoblastic leukemia 3 decades ago. Long-term survival data (minimum follow-up >10 years) is now available. About 3711 eligible children were enrolled in risk-adjusted treatment protocols (1983–1989). Ten-year event-free survival (EFS) and overall survival were 62% (standard deviation [SD] = 1%) and 73% (SD = 1%). These data showed a significant improvement (P< 0.0001) compared with the predecessor studies. Since 11% of patients with initial relapses survived without second events, these data predicted a cure rate of 73%. Ten-year EFS and survival were improved significantly for patients with intermediate risk (P< 0.0001), high risk (P< 0.0001) and lymphomatous features (P< 0.0001). Key components of therapies included delayed intensification and substitution of intrathecal chemotherapy for prophylactic/preventive cranial radiation in low- and intermediate-risk patients. This is the largest series of children on concurrent studies who were observed more than 10 years.